Matic-FX Chewable Tablet contains Montelukast 10 mg and Fexofenadine 120 mg, combining the therapeutic effects of a leukotriene receptor antagonist and a second-generation antihistamine. Montelukast acts by selectively blocking leukotriene D4 receptors in the respiratory tract, thereby reducing inflammation, bronchoconstriction, and mucus production associated with allergic rhinitis and asthma. Fexofenadine, a non-sedating antihistamine, competitively inhibits peripheral H1 receptors, alleviating symptoms such as sneezing, nasal congestion, runny nose, and itchy or watery eyes commonly observed in seasonal allergic rhinitis and chronic urticaria. The chewable formulation facilitates ease of administration, particularly in pediatric and geriatric populations who may have difficulty swallowing conventional tablets. Matic-FX is indicated for the management of allergic rhinitis, chronic idiopathic urticaria, and as an adjunct in asthma control where allergic components are involved. It offers the advantage of dual-action symptom relief by addressing both histamine-mediated and leukotriene-mediated pathways. Patients should use this medication under medical supervision, adhering to prescribed dosages to minimize potential adverse effects such as headache, dizziness, gastrointestinal discomfort, or hypersensitivity reactions. This combination therapy provides a convenient and effective option for comprehensive allergy symptom management.